Nasdaq GlobeNewswire

ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

Del

Key updates

  • QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.
  • A clinically meaningful improvement of CF respiratory symptoms, as measured by CFQ-R RSS, was observed in 3 out of 4 multiple dose groups with a mean improvement of 13.0 to 19.2 points compared to placebo. In a pre-defined subgroup of subjects with a lower lung function at baseline, the mean improvement was up to 27.5 points compared to placebo.
  • Magnitude of the benefit observed in CFQ-R RSS for these dose groups exceeded the established minimal clinically important difference of 4.0 points.
  • In the same multiple dose groups a supportive trend of improved lung function was observed up to 4.0% mean absolute change in ppFEV1compared to placebo. In a pre-defined subgroup of subjects with a lower lung function at baseline a mean absolute change in ppFEV1 was observed up to 10.9% compared to placebo.
  • After inhaled administration in some dose groups, QR-010 was detected in the blood.
  • ProQR and the Cystic Fibrosis Foundation Therapeutics intend to expand their partnership to explore the inhaled oligonucleotide platform to target stop-codon mutations in CF.
  • Management will discuss the top-line results during a conference call today at 5 pm ET.

LEIDEN, the Netherlands, Sept. 25, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced positive preliminary top-line results from a Phase 1b safety and tolerability clinical trial (Study PQ-010-001; NCT02532764) of QR-010, a novel investigational RNA therapeutic in subjects with cystic fibrosis (CF). Full data from the trial will be presented at the North American CF Conference (NACFC) on November 2-4, 2017.

Study PQ-010-001 was a Phase 1b, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of QR-010 in adult subjects with CF homozygous for the F508del mutation. This trial studied 4 dose levels of QR-010 administered via inhalation in 4 single-dose and 4 multiple-dose groups. A number of exploratory efficacy endpoints were assessed in the multiple dose groups: respiratory symptoms (as measured by a validated patient-reported outcome tool, the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS), lung function (as measured by mean absolute change in percent predicted forced expiratory volume in 1 second, or ppFEV1), sweat chloride test and weight change. This study included subjects with, on average, a normal lung function at baseline (mean ppFEV1 86%, range 69-116%). As therapeutic trials typically study subjects with normal-to-severe lung function at baseline (ppFEV1 <90%), a subgroup was pre-defined to analyze the exploratory efficacy endpoints in this population. The trial recruited 70 participants and was conducted at 23 sites in 10 countries in Europe and North America.

J. Stuart Elborn, the principal investigator of the study, Clinical Chair in Respiratory Medicine at Imperial College, Consultant at Royal Brompton Hospital, and immediate past-president of the European Cystic Fibrosis Society, added, "QR-010 exceeded expectations in this study as an innovative investigational therapy for the treatment of cystic fibrosis for which the need remains high. The improvements demonstrated in reduction of respiratory symptoms are very encouraging and intriguing and of course of enormous importance to people with CF. The results of this study together with the previous proof of concept study are strongly supportive of the further development of QR-010."

Top-Line Results

In this trial QR-010 was observed to be safe and well-tolerated across all doses, with an overall safety profile similar to placebo. There were no serious adverse events related to treatment. After inhaled administration in some dose groups, QR-010 was detected in the blood. Subjects who received QR-010 in the 6.25, 12.5 and 25 mg multiple dose groups reported fewer respiratory symptoms after 4 weeks of treatment as measured by the increased CFQ-R RSS, with mean improvements of 13.0, 19.2 and 14.3 points, respectively, compared to placebo. The effect was more pronounced in the pre-defined subgroup of subjects with a lower lung function at the start of the study (baseline ppFEV1 70-90%) with a mean increase of up to 27.5 points compared to placebo. These improvements exceeded the minimal clinically important difference (MCID) of 4.0 points. A supportive trend of improved lung function was observed in the same multiple dose groups, as measured by mean absolute change in ppFEV1 compared to placebo. The trend was stronger in the subgroup of subjects with a lower lung function at baseline. The table below summarizes the data per multiple dose group. As expected, no effect was observed on sweat chloride and weight.

        Per protocol population
    Pre-defined subgroup of subjects with
baseline ppFEV1 70-90%
            CFQ-R RSS
    ppFEV1
          CFQ-R RSS
    ppFEV1
Groups 
(12 doses
over 4
weeks)
      n     mean change vs
placebo 
(p-value)
    95% CI     mean absolute
%
change vs
placebo 
(p-value)
    95% CI     n     mean
change vs
placebo 
(p-value)
    95% CI     mean absolute % 
change vs
placebo 
(p-value)
    95% CI
6.25 mg       6     +13.0 (0.0585)     -0.5 ; 26.4     +1.2 (0.7266)     -6.0 ; 8.4     3     +23.2 (0.0315)     2.4 ; 44.1     +8.0 (0.1613)     -3.6 ; 19.5
12.5 mg       6     +19.2 (0.0072)     5.7 ; 32.7     +4.0 (0.2626)     -3.2 ; 11.2     4     +27.5 (0.0095)     7.9 ; 47.1     +10.9 (0.0461)     0.2 ; 21.6
25 mg       6     +14.3 (0.0399)     0.7 ; 27.9     -0.2 (0.9664)     -7.3 ; 7.1     5     +20.3 (0.0334)     1.9 ; 38.7     +4.7 (0.3410)     -5.5 ; 14.8
50 mg       5     +3.5 (0.6182)     -10.7 ; 17.6     -0.6 (0.8749)     -8.2 ; 7.0     4     +10.9 (0.2463)     -8.4 ; 30.2     +3.7 (0.4745)     -7.0 ; 14.3
Placebo       8     -6.5     -15.3 ; 2.4     -0.8     -5.5 ; 3.9     4     -11.8     -25.5 ; 2.0     -3.8     -11.3; 3.8

The Phase 1b study achieved its goals for evaluation of QR-010 including demonstrating safety and tolerability across a range of doses, identified a dosing window, exhibited uptake of the RNA oligonucleotide into circulation following inhalation, and demonstrated early signals of clinical efficacy.

"The positive results in the first two clinical trials of QR-010 significantly increase the confidence that QR-010 has the potential to become an effective treatment of CF. The improvement in CFQ-R RSS with the supportive FEV1 data as shown in this Phase 1b trial is very exciting," said Noreen R. Henig, M.D, Chief Medical Officer at ProQR. "I want to thank the entire CF community including those living with CF, clinical investigators, scientists, the CF Foundation, the European CF Society and the US and European therapeutic development networks for their unwavering commitment."

Partnership with Cystic Fibrosis Foundation Therapeutics (CFFT)

ProQR and CFFT entered into a partnership in 2014 to develop QR-010 for people with CF due to the F508del mutation. The initial partnership included support for the Phase 1b trial as well as the NPD proof of concept study that reported positive results in 2016. Based on the results of the clinical trials of QR-010, ProQR and CFFT intend to expand the partnership to explore the inhaled oligonucleotide platform for stop-codon mutations (also called "Class I" mutations) in CFTR. Stop-codon mutations cannot be targeted with small molecule potentiator or corrector molecules, and therefore have a high unmet medical need. ProQR intends to target these mutations using its proprietary Axiomer® technology, which has shown compelling data in non-clinical studies, to repair the stop-codon mutations in the RNA, leading to removal of the premature stop-codon. Approximately 12,000 patients, accounting for 15% of CF patients in the western world, have a stop-codon mutation leading to a severe form of CF.

"The results of this Phase 1b trial support QR-010's potential to be a meaningful therapy for people with cystic fibrosis," said Daniel A. de Boer, Chief Executive Officer at ProQR. "With these results in hand we are designing a path forward for the development of QR-010, either independently or with a potential partner. Furthermore we are looking forward to expanding our partnership with the CFFT to explore the inhaled oligonucleotide platform also for people that have CF due to stop-codon mutations."

About the PQ-010-001 Trial

The Phase 1b study was a trial designed to assess safety, tolerability and pharmacokinetics of QR-010. A number of exploratory efficacy endpoints were assessed in the multiple dose groups. A total of 4 dose levels were studied: 6.25, 12.5, 25 and 50 mg of QR-010 in solution per dose administered via inhalation using the PARI eFlow® nebulizer. Subjects eligible to participate were males and females of 18 years and over with a ppFEV1 of greater than or equal to 70% at time of inclusion, homozygous for the F508del mutation, and not taking CFTR modulator drugs. The study design planned to enroll 8 cohorts of 8 subjects (6 receiving QR-010, 2 receiving placebo). In cohorts 1-4, a single dose of QR-010 was administered, and in cohorts 5-8 twelve doses of QR-010 were administered over a 4-week period.

QR-010 Milestones

  • Technology for QR-010 in-licensed from Massachusetts General Hospital in 2012.
  • Partnership with the CFF established to develop QR-010 for patients with the F508del mutation.
  • In vitro proof of concept in three F508del CF assays.
  • In vivo proof of concept in two assays, including nasal potential difference (NPD).
  • Pre-clinical in vitro and in vivo proof of concept established for efficient inhaled delivery to the CF diseased lung in collaboration with the University of North Carolina at Chapel Hill.
  • QR-010 granted fast-track status by the FDA and orphan drug designation from FDA and the European Commission.
  • Program received funding from the European Union's Horizon 2020 research and innovation programme.
  • Clinical trial PQ-010-002 top-line data shows significant improvement of CFTR function as measured by NPD in subjects homozygous for the F508del mutation following topical administration of QR-010.
  • Grant of two key patents, protecting QR-010 in the US and Europe.
  • Preliminary top-line data from clinical trial PQ-010-001 shows QR-010 is detected in the blood after inhaled administration, was observed to be safe and well-tolerated and shows signals of efficacy.
  • Full data for PQ-010-001 will be presented at the NACFC (November 2-4, 2017).

Conference Call and Webcast Information

ProQR will host a conference call and webcast today at 5:00 PM Eastern Time (ET) or 11:00 PM Central European Time (CET). The conference call will be webcast live and a link to the webcast can be accessed through ProQR's website (www.proqr.com) and in the "Investors" section under "Events and Presentations". To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. To participate in the conference call, please dial in 5-10 minutes prior to start time and reference Conference ID 8468989:

             
Country     Toll Free     Direct
US     1 877 280 2296     +1 646 254 3365
Netherlands     0800 020 2576     +31 (0) 20 713 2789
United Kingdom     0800 279 4977     +44 (0) 20 3427 1919
Germany     0800 589 2674     +49 (0) 69 2222 10620
Belgium     0800 58032     +32 (0) 2 400 3463
Switzerland     0800 345 603     +41 (0) 44 580 7214
France     0805 631 580     +33 (0) 1 7677 2222

About QR-010

QR-010 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of the disease by targeting the mRNA in CF patients that have the F508del mutation. The technology was exclusively licensed from Massachusetts General Hospital. The F508del mutation results in the production of a misfolded CFTR protein that does not function normally. QR-010 is a single agent designed to bind to the defective CFTR mRNA and to restore CFTR function. QR-010 is designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma GmbH). eFlow® is a small, handheld aerosol delivery device which nebulizes QR-010 into a mist inhaled directly into the lungs. QR-010 has been granted orphan drug designation in the United States and the European Union and fast-track status by the FDA. The QR-010 project received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 633545.

About Cystic Fibrosis

Cystic fibrosis (CF) is the most common fatal inherited disease in the Western world and affects over 75,000 patients worldwide. In people with CF, a defective CFTR gene causes a thick buildup of mucus in the lungs, pancreas and other organs. In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage and eventually, respiratory failure. There is no cure for CF. Disease manifestations lead to a shortened life expectancy with a median age of death of 30 years. Although over 1,900 CF-causing gene mutations have been identified, approximately 85% of all CF patients are affected by the F508del mutation. Among all CF patients, approximately 50% are homozygous for the F508del mutation.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. 
*Since 2012*

FORWARD-LOOKING STATEMENTS  

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding QR-010, including its clinical development and therapeutic potential, including future development plans, and statements regarding the partnership with CFFT. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, including that positive results observed in our prior and ongoing studies may not be replicated in later trials or guarantee approval of any product candidate by regulatory authorities, that a Fast Track designation by the FDA may not actually lead to a faster development, regulatory review or approval process, and that we may not be able to realize the potential benefits of orphan drug exclusivity, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

ProQR Therapeutics N.V.:
Media Contact:
Sariette Witte
T: +31 6 2970 4513 (NL)
T: + 1 213 261 8891 (US)
pr@proqr.com

Investor Contact:
Bonnie Ortega
T: +1 858 245 3983
ir@proqr.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProQR Therapeutics N.V. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

SD-WAN Market Leader Aryaka Further Expands UK and EMEA Market Reach with Intergence Partnership21.2.2018 16:01Pressemelding

Partnership Enables More UK and EMEA Enterprises to Adopt Global SD-WAN as-a-Service LONDON, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, today announced that Cambridge, UK-based Intergence will deploy Aryaka's global SD-WAN solution to enhance global connectivity and application performance for its enterprise customers with offices in the UK and Europe. Partnering with Aryaka strengthens Intergence's infrastructure services proposition for its global enterprise customers. Intergence comprises a team of IT infrastructure experts that help organizations realize their digital transformation objectives. Formed in 2003, the company uses innovative technologies like its Stratiam(TM) solution to provide CIOs with insights about IT performance and the customer's digital experiences, and to simplify complex IT problems. Intergence's infrastructure services provide IT leaders with greater flexibility, agility, and cost efficiency. The partnership will enable In

TrueCommerce Dynamics 365 Solution Featured on Microsoft AppSource21.2.2018 16:00Pressemelding

TrueCommerce Solution Delivers Powerful Supply Chain Integration Capabilities to Dynamics 365 Community PITTSBURGH, Feb. 21, 2018 (GLOBE NEWSWIRE) -- TrueCommerce, a global provider of trading partner connectivity and integration solutions, has announced today that its Microsoft Dynamics 365 solution is available on Microsoft AppSource. Built exclusively for and within the native Dynamics 365 platform, the embedded solution connects directly with TrueCommerce's global commerce network, offering immediate access to more than 92,000 pre-connected retailers, marketplaces, distributors, vendors and logistics providers. "Our solution for Dynamics 365 offers a multi-company, multi-deployment architecture that scales to support complex enterprise requirements," said TrueCommerce president Ross Elliott. "We are excited to be selected as one of the few EDI solutions to be featured on Microsoft AppSource, recognition of having achieved Microsoft's highest standards for quality and reliability fo

Announcing North America's Most Advanced Radio Access Network Solution by GCI in Collaboration with Altiostar21.2.2018 15:00Pressemelding

ANCHORAGE, Alaska, Feb. 21, 2018 (GLOBE NEWSWIRE) -- GCI, Alaska's largest telecommunications provider announced today that it has selected Altiostar to supply virtualized RAN (vRAN) technology to support GCI's LTE-Advanced network deployment and to lay the foundation for 5G and IoT. The technology will allow GCI to expand network coverage and improve capacity, and thus enhance end-user experience. Over the last 12 months GCI has been conducting field trials in Anchorage and Fairbanks with this solution from Altiostar, and this contract award is the result of this validation of the vRAN technology. Altiostar will introduce its LTE-Advanced technologies such as 4x4 MIMO and Multi-band Carrier Aggregation to significantly enhance end user experience for data applications and better voice quality using Voice over LTE (VoLTE). LTE 4x4 MIMO enables better mobile broadband coverage and data throughput for GCI subscribers, and increased spectral efficiency for GCI. GCI customers will benefit

Colliers International Named to IAOP® Global Outsourcing 100 List for 13th Consecutive Year21.2.2018 15:00Pressemelding

International Association of Outsourcing Professionals® Honors Colliers in Its Annual Listing of the World's Best Outsourcing Service Providers TORONTO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) is pleased to announce that it has again been selected for The 2018 Global Outsourcing 100 list by IAOP®, an honor the company has earned for 13 straight years, more than any other real estate services provider. Colliers has been named to the list each year since its inception. Colliers is committed to leadership in the global outsourcing industry and has a proven track-record in the space. The company's outstanding growth continues through a focus on maintaining the most collaborative and creative culture in the industry, allowing clients to accelerate their success by sharing its market-leading expertise. "We are honored to again receive this prestigious recognition from IAOP," said Dylan Ta

New cyber-risk conference coming to Bermuda in 201821.2.2018 14:44Pressemelding

HAMILTON, Bermuda, Feb. 21, 2018 (GLOBE NEWSWIRE) -- A new Bermudian edition of a successful North American cyber-risk conference will be held later this year, the Bermuda Business Development Agency (BDA) has announced. The inaugural International Cyber Risk Management Conference (ICRMC) Bermuda, presented by Canada's MSA Research Inc, will take place December 6-7 at the Hamilton Princess & Beach Club, following a BDA invitation to bring the event to the island. ICRMC Bermuda will be designed for corporate risk managers, corporate counsel, auditors, CISOs, CSOs, and CTOs, governance and claims professionals, insurers, reinsurers, insurance brokers and service providers. The BDA will be signature sponsor of the two-day conference that follows the company's popular Toronto event, happening April 11-12. "We are proud to bring ICRMC to Bermuda, the 'World's Risk Capital,' where we, with the support of a stellar steering committee, will focus on cyber risk with an emphasis on re/insurance

Cisco 2018 Annual Cybersecurity Report Reveals Security Leaders Rely on and Invest in Automation, Machine Learning and Artificial Intelligence to Defend Against Threats21.2.2018 14:00Pressemelding

Findings show 39 percent of organizations are reliant on automation, 34 percent are reliant on machine learning, 32 percent are highly reliant on AI SAN JOSE, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Malware sophistication is increasing as adversaries begin to weaponize cloud services and evade detection through encryption, used as a tool to conceal command-and-control activity. To reduce adversaries' time to operate, security professionals said they will increasingly leverage and spend more on tools that use AI and machine learning, reported in the 11th Cisco® 2018 Annual Cybersecurity Report (ACR). While encryption is meant to enhance security, the expanded volume of encrypted web traffic (50 percent as of October 2017) - both legitimate and malicious - has created more challenges for defenders trying to identify and monitor potential threats. Cisco threat researchers observed more than a threefold increase in encrypted network communication used by inspected malware samples over a

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom